PNQ 154
Alternative Names: PNQ-154Latest Information Update: 28 Jul 2024
At a glance
- Originator Advinus Therapeutics
- Developer Impetis Biosciences
- Class Antineoplastics; Antirheumatics; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Diffuse large B cell lymphoma; Mantle-cell lymphoma; Rheumatoid arthritis
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Diffuse large B cell lymphoma in India (PO)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Mantle-cell-lymphoma in India (PO)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in India (PO)